Fluoride Action Network


Purpose: How coronary arterial 18F-sodium fluoride (18F-NaF) uptake on positron emission tomography changes over the long term and what clinical factors impact the changes remain unclear. We sought to investigate the topics in this study.

Methods: We retrospectively studied 15 patients with >1 coronary atherosclerotic lesion/s detected on cardiac computed tomography who underwent baseline and follow-up (interval of >3 years) 18F-NaF positron emission tomography/computed tomography scans. Focal 18F-NaF uptake in each lesion was quantified using maximum tissue-to-background ratio (TBRmax). The temporal change in TBRmax was assessed using a ratio of follow-up to baseline TBRmax (R-TBRmax).

Results: A total of 51 lesions were analyzed. Mean R-TBRmax was 0.96 ± 0.21. CT-based lesion features (location, obstructive stenosis, plaque types, features of high-risk plaque) did not correlate with an increase in R-TBRmax. In multivariate analysis, baseline TBRmax significantly correlated with higher follow-up TBRmax ( = 0.57, P < 0.0001), and the presence of diabetes mellitus significantly correlated with both higher follow-up TBRmax (B = 0.34, P = 0.001) and elevated R-TBRmax (B = 0.40, P = 0.003).

Conclusion: Higher coronary arterial 18F-NaF uptake is likely to remain continuously high. Diabetes mellitus affects the long-term increase in coronary arterial 18F-NaF uptake.

Keywords: Atherosclerosis; CAD; Diseases/processes; Modalities; Molecular imaging agents; PET; Tests; Tracers; Vascular imaging.

*Original study online at https://link.springer.com/article/10.1007/s12350-022-02975-w



1. Derlin T, Tóth Z, Papp L, Wisotzki C, Apostolova I, Habermann CR. Correlation of inflammation assessed by 18F-FDG PET, active mineral deposition assessed by 18F-fluoride PET, and vascular calcification in atherosclerotic plaque: a dual tracer PET/CT study. J Nucl Med 2011;52:1020?7. – DOI

2. Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, et al. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol 2012;59:1539?48. – DOI

3. Ishiwata Y, Kaneta T, Nawata S, Hino-Shishikura A, Yoshida K, Inoue T. Quantification of temporal changes in calcium score in active atherosclerotic plaque in major vessels by 18F-sodium fluoride PET/CT. Eur J Nucl Med Mol Imaging 2017;44:1529?37. – DOI

4. Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet 2014;383:705?13. – DOI

5. Kitagawa T, Yamamoto H, Nakamoto Y, Sasaki K, Toshimitsu S, Tatsugami F, et al. Predictive value of 18F-sodium fluoride positron emission tomography in detecting high-risk coronary artery disease in combination with computed tomography. J Am Heart Assoc 2018;7:e010224. – DOI

6. Kwiecinski J, Tzolos E, Adamson PD, Cadet S, Moss AJ, Joshi N, et al. Coronary 18F-sodium fluoride uptake predicts outcomes in patients with coronary artery disease. J Am Coll Cardiol 2020;75:3061?74. – DOI

7. Lee JM, Bang JI, Koo BK, Hwang D, Park J, Zhang J, et al. Clinical relevance of 18F-sodium fluoride positron-emission tomography in noninvasive identification of high-risk plaque in patients with coronary artery disease. Circ Cardiovasc Imaging 2017;10:e006704. – DOI

8. Kitagawa T, Yamamoto H, Toshimitsu S, Sasaki K, Senoo A, Kubo Y, et al. 18F-sodium fluoride positron emission tomography for molecular imaging of coronary atherosclerosis based on computed tomography analysis. Atherosclerosis 2017;263:385?92. – DOI

9. Raff GL, Abidov A, Achenbach S, Berman DS, Boxt LM, Budoff MJ, et al. SCCT guidelines for the interpretation and reporting of coronary computed tomographic angiography. J Cardiovasc Comput Tomogr 2009;3:122?36. – DOI

10. Moss AJ, Doris MK, Andrews JPM, Bing R, Daghem M, van Beek EJR, et al. Molecular coronary plaque imaging using 18F-fluoride. Circ Cardiovasc Imaging 2019;12:e008574. – DOI

11. Reijrink M, de Boer SA, Te Velde-Keyzer CA, Sluiter JKE, Pol RA, Heerspink HJL, et al. [18F]FDG and [18F]NaF as PET markers of systemic atherosclerosis progression: a longitudinal descriptive imaging study in patients with type 2 diabetes mellitus. J Nucl Cardiol 2021. https://doi.org/10.1007/s12350-021-02781-w . – DOI PubMed

12. Takx RAP, van Asperen R, Bartstra JW, Zwakenberg SR, Wolterink JM, Celeng C, et al. Determinants of 18F-NaF uptake in femoral arteries in patients with type 2 diabetes mellitus. J Nucl Cardiol 2020;28:2700?5. – DOI